Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024